This clinical trial is focused on studying a condition known as chronic rhinosinusitis with nasal polyps. This is a long-term inflammation of the sinuses that leads to the growth of polyps, which are small, non-cancerous swellings inside the nasal passages. The trial will test a treatment called itepekimab, which is a type of medication known as a monoclonal antibody. Monoclonal antibodies are proteins made in a lab that can bind to specific substances in the body. Itepekimab is designed to target and block a protein called interleukin-33, which is involved in the inflammation process.

The purpose of the study is to evaluate how effective itepekimab is in reducing the size of nasal polyps and relieving nasal congestion compared to a placebo. Participants in the study will receive either itepekimab or a placebo through a subcutaneous injection, which means the medication is injected under the skin. The study will last for 52 weeks, during which participants will be monitored for changes in their symptoms and any side effects they might experience.

Throughout the study, participants will undergo various assessments to track their progress. These assessments will include checking the size of the nasal polyps and the level of nasal congestion. The study will also look at other symptoms like loss of smell and sinus opacification, which refers to the cloudiness seen in the sinuses on a computed tomography (CT) scan. The trial aims to provide valuable information on the safety and effectiveness of itepekimab for people with chronic rhinosinusitis with nasal polyps.